一种潜在的炎症生物标志物,用于先进的子宫内膜癌,用lenvatinib加上 pembrolizumab治疗
Shintaro Yanazume1, Yusuke Kobayashi1, Yukari Kirita2
1Department of Obstetrics and Gynecology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
The journal of obstetrics and gynaecology research
|December 23, 2024
概括
在lenvatinib/pembrolizumab治疗之前,外围血液中性粒细胞与淋巴细胞的比率 (NLR) 在预测晚期子宫内膜癌患者无进展生存的预测中显示出希望. 这种炎症生物标志物可以指导治疗决策.
科学领域:
- 在瘤学瘤学.
- 生物标志物发现发现
- 免疫治疗是一种免疫疗法.
背景情况:
- 鉴定预后生物标志物对于预测患者对伦巴替尼布/布利祖马布 (LEN/PEM) 治疗的反应至关重要.
- 研究的炎症生物标志物,包括中性粒细胞计数,淋巴细胞计数和中性粒细胞与淋巴细胞比率 (NLR),在基于液体的细胞学 (LBC) 和外周血液中.
研究的目的:
- 确定预后生物标志物,以预测晚期或复发性子宫内膜癌患者对伦瓦提尼布/佩姆布利祖马布 (LEN/PEM) 的反应.
- 评估子宫内膜LBC和外周血液样本中炎症标记物的预测效用.
主要方法:
- 对25名先进/复发性子宫内膜癌患者的回顾性分析,这些患者接受了LEN/PEM治疗.
- 结核细胞/淋巴细胞数量和从子宫内膜LBC和周围血液中的NLR作为总体反应和无进展生存的预测指标,使用ROC曲线,日志级别测试和多变量分析进行了比较.
主要成果:
- 与外周血液标志物相比,子宫内膜LBC中性粒细胞计数和NLR是总体反应的较不有效预测指标.
- 在LEN/PEM治疗前的外周血液NLR是无进展状态的最准确预测指标 (AUC=0.722).
- 在治疗前较低的外周血液NLR (<5.39) 与较长的无进展生存时间 (中位数为13.5vs3.0个月,p=0.023) 有显著的关联.
结论:
- 在子宫内膜LBC中的炎症生物标志物不能可靠地预测lenvatinib/pembrolizumab的疗效.
- 在lenvatinib/pembrolizumab治疗前采集的外周血液NLR样本显示,它有可能成为内膜腺癌无进展生存的显著预后生物标志物.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...